Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661787 | 0.71 | PARP15 (0.35) | TNKS2PARP2PARP15IDO1L3MBTL1 | |
| SCHEMBL1154852 | 0.68 | ACKR3 (0.33) | ALOX15 | |
| SCHEMBL1155067 | 0.67 | PARP15 (0.32) | TNKS2PARP2PARP15L3MBTL1 | |
| SCHEMBL19438287 | 0.64 | POLB (0.35) | TOP2AALOX15 | |
| SCHEMBL276894 | 0.62 | ALDH1A1 (0.40) | L3MBTL1ALOX15 | |
| SCHEMBL16320814 | 0.62 | PDE10A (0.42) | TOP2A | |
| SCHEMBL16402571 | 0.62 | POLB (0.44) | TOP2AALOX15 | |
| SCHEMBL9934485 | 0.62 | POLB (0.34) | TOP2AALOX15 | |
| SCHEMBL20689186 | 0.62 | DHFR (0.36) | L3MBTL1TOP2AALOX15 | |
| SCHEMBL4219167 | 0.62 | IDO1 (0.47) | TDO2IDO1L3MBTL1TBXAS1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | IGF1R, IGFBP3, INSR | TNKS2 2856/4885PARP2 2046/4885PARP15 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.